SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board: 
Last Post: 4/23/2017 11:04:23 PM - Followers: 824 - Board type: Free - Posts Today: 0

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:48:03 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:42:25 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:27:37 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:19:06 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:10:49 PM
#248717  Sticky Note Elite Pharmaceuticals is starting to look a lot IB_ 03/31/17 01:32:55 PM
#247416  Sticky Note HERE is WHAT long term investors need to UNDERSTAND!!! Couch 03/21/17 06:12:24 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#251602   Please let me know the last time Elite jour_trader 04/23/17 11:04:23 PM
#251601   Fumblings & mistakes along the way at a jour_trader 04/23/17 11:01:42 PM
#251600   NDA submissions are pointless without approvals. The proof jour_trader 04/23/17 11:00:31 PM
#251599   Are you for real? We will get a jour_trader 04/23/17 10:55:50 PM
#251598   Commentary on a board doesn't make your shares Goodtimes93 04/23/17 09:45:05 PM
#251597   You mean the common sense that Elite and Gman24 04/23/17 09:28:05 PM
#251596   The fancy wording from dr Google search misses Goodtimes93 04/23/17 09:00:43 PM
#251595   SequestOx will not be approved this July 14th IB_ 04/23/17 08:29:37 PM
#251594   Positive BE data coming by Mid May - Couch 04/23/17 06:31:44 PM
#251593   true genius is understanding that elite is overvalued dr_lowenstein 04/23/17 06:24:09 PM
#251590   That Elite is undervalued comparatively. Doesn't take a mrwrn2010 04/23/17 01:02:30 PM
#251588   Well, if given the choice, any reasonable Elite no2koolaid 04/23/17 12:25:47 PM
#251587  Restored and the point of that is?????? LOL LOL dr_lowenstein 04/23/17 12:24:07 PM
#251586   Thanks and I see that I was remiss no2koolaid 04/23/17 12:16:12 PM
#251585   SequestOx approval trumps all 3 of those $$$$$$$$$$$ Couch 04/23/17 12:08:40 PM
#251584   3 ROADS leading to FINANCIAL RUIN buy, hold stockboy 04/23/17 11:38:24 AM
#251583   Lets stick with FACTS Couch 04/23/17 11:38:10 AM
#251582   11 Roads to DollarLand NASDAQ2020 04/23/17 09:06:11 AM
#251581   Lets stick with FACTS namtae 04/23/17 08:48:03 AM
#251580   Great post NASDAQ2020 04/23/17 08:46:16 AM
#251579   There is hope, Elite is in N.J. sharkey1 04/23/17 08:07:40 AM
#251578   SequestOx™ given Green Light by FDA NASDAQ2020 04/23/17 07:59:35 AM
#251577   Gee point out one single time when Elite Couch 04/23/17 07:53:14 AM
#251576   Sure K; Positive BE data coming by Mid May. Couch 04/23/17 07:50:26 AM
#251575   If these results aren't good then it may Couch 04/23/17 07:49:11 AM
#251574   a resubmission of SequestOx has taken far far Couch 04/23/17 07:47:10 AM
#251573   .06 to .97 and going to run again. Couch 04/23/17 07:45:47 AM
#251572   but I don't see it. Couch 04/23/17 07:43:26 AM
#251571   Everyone knows Couch 04/23/17 07:34:19 AM
#251570   Good job pointing out the never ending BS namtae 04/23/17 06:00:31 AM
#251569   Please show PROOF where it says NasRAT will stockboy 04/23/17 01:06:24 AM
#251568   That is completely inaccurate. Year end call is jour_trader 04/22/17 11:54:06 PM
#251567   Going to be an interesting year. John_Langston 04/22/17 11:53:40 PM
#251566   Fine for me. I am in the green jour_trader 04/22/17 11:52:06 PM
#251565   Only 3 PATHWAYS to FINANCIAL RUIN buy, hold, stockboy 04/22/17 11:09:01 PM
#251564   So sad nasRAT can't hit just one. John_Langston 04/22/17 11:08:33 PM
#251563   Of course he's been over promising and under stockboy 04/22/17 11:06:59 PM
#251562   One more CRL away from CPR for Elite. John_Langston 04/22/17 11:00:30 PM
#251561   11 Pathways to DollarLand and Beyond NASDAQ2020 04/22/17 10:04:26 PM
#251560   One Launch away from CFP! NASDAQ2020 04/22/17 09:57:06 PM
#251559   If these results aren't good then it may John_Langston 04/22/17 09:19:53 PM
#251558   If the results are positive in May John_Langston 04/22/17 09:11:45 PM
#251557   That one "If" is why I buy penny John_Langston 04/22/17 09:10:12 PM
#251556   Also, a summary of results is fine for jour_trader 04/22/17 08:57:15 PM
#251555   If the results are positive in May, the jour_trader 04/22/17 08:52:45 PM
#251554   Nasrat made sure he got his no risk namtae 04/22/17 08:17:59 PM
#251553   Theyve admitted to needing an extra $2-3m just John_Langston 04/22/17 08:03:48 PM
#251552   Well, nasrat is forced to spend on Elite namtae 04/22/17 08:01:47 PM
#251551   With the OS about maxed out and the John_Langston 04/22/17 07:52:01 PM
#251550   They are accurate in some senses but theories Goodtimes93 04/22/17 07:44:36 PM